Abiomed Inc. reported that the first patient to commercially receive its AbioCor self-contained artificial heart died August 23 due to post-operative conditions unrelated to the device.

The 76-year-old man was implanted with the $250,000 device June 15 and died August 23. Abiomed said the deceased is survived by his wife and other family members. Chairman, president and CEO Michael Minogue said the company’s thoughts and prayers are with the family.

It was the first commercial implantation since the Danvers cardiac device maker’s artificial heart went through clinical trials and won humanitarian device exemption approval from the Food & Drug Administration in 2006.

The device, which made headlines early this decade as the first self-contained artificial heart, is designed for patient with acute heart failure who don’t qualify for a transplant. The device is designed to run for 18 to 24 months after implantation, Minogue told MassDevice when the implantation was announced in June.